Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer

摘要: Purpose: Patients with non-small cell lung carcinoma epidermal growth factor receptor ( EGFR ) mutations may have a more favorable prognosis and greater response to chemotherapy. The effect of mutation gene copy on patients early-stage receiving adjuvant chemotherapy has not been reported. Methods: Tumor samples from NCIC Clinical Trials Group JBR.10, an trial vinorelbine/cisplatin [ACT] versus observation (OBS), were analyzed for by multiple sensitive methods number fluorescent in situ hybridization. Their prognostic predictive roles explored correlation survival. Results: Mutation results available 221 OBS 215 ACT hybridization 159 163 patients. Mutations identified 43 (27 16 ACT) (36 sensitizing exon 19 deletions or L858R mutations). Compared wild-type, significantly (hazard ratio [HR]: 0.79, 95% confidence interval [CI]: 0.38–1.63, p = 0.53). Although the presence resulted relatively benefit (HR: 0.44, CI: 0.11–1.70, 0.22) compared wild-type 0.78, 0.58–1.06, 0.12), this quantitative difference was significant (interaction 0.50). Similarly, high neither nor predictive, although quantitatively it associated ACT. Conclusions: Trends toward longer survival observed 19/21 copy, differences statistically significant. interpretation limited low rate study mainly white